Aktie A110YV REGEN BIOPHARMA, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Regen BioPharma, Inc. Other OTC

Aktien

A110YV

US75886M1027

RGBP

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
Regen BioPharma, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023
Regen BioPharma, Inc. Outlines Future Steps in CAR T Program
Regen BioPharma, Inc Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program
Regen Biopharma, Inc. Expects Second Phase of Confirmatory Study Shortly
Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer
Studies on Regen Biopharma, Inc.'s Duracar Indicate Potential Suppression of Autoimmunity, Company Retains Contract Research Organization to Conduct Additional Confirmatory Studies
Regen BioPharma, Inc. announced that it has received $0.14875 million in funding
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on August 10, 2023
Regen BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023
Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023
REGEN BIOPHARMA INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)
Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio
REGEN BIOPHARMA INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022
Regen BioPharma, Inc. Announces Board Appointments
Regen BioPharma : Private Placement - Form 8-K
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3D704 Aktie
  4. A110YV Aktie
  5. Nachrichten Regen BioPharma, Inc.
  6. Andere Sprachen